REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2023.
“We started the year off strong with continued growth in our installed base and progress against our strategic objectives. It is exciting to see the Proteograph enable breakthrough science, with increasing data demonstrating its power, extensibility, and catalyzation of new applications,” said Omid Farokhzad, CEO and President. “We are seeing more data being generated by our customers, the initiation of larger studies, and the first customer publications make their way through the peer-review process. We expect this momentum to continue throughout the year as more customers adopt the technology and scale their use of the platform.”
Recent Highlights
First Quarter 2023 Financial Results
Revenue was $4.1 million for the three months ended March 31, 2023, a 22% increase from $3.3 million for the three months ended March 31, 2022. The increase was primarily due to increased sales of consumable kits related to the Proteograph Product Suite. Product-related revenue for the first quarter of 2023 was $3.6 million, including $1.3 million of related party revenue, and consisted of sales of SP100 instruments, consumable kits and platform evaluations. Service revenue was $0.1 million and grant and other revenue was $0.3 million.
Gross profit, inclusive of grant and other revenue, was $2.1 million and gross margin was 51% for the first quarter of 2023.
Operating expenses were $29.5 million for the first quarter of 2023, including $8.7 million of stock-based compensation, an increase of 18%, as compared to $25.0 million, including $8.1 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation, product development efforts related to the Proteograph Product Suite, and expenses associated with build-out of expansion facilities.
Net loss was $24.0 million for the first quarter of 2023, as compared to $23.6 million for the corresponding prior year period.
Cash, cash equivalents and investments were $410.5 million as of March 31, 2023.
2023 Guidance
Seer continues to expect full year 2023 revenue to be in the range of $23 million to $25 million, representing growth of 48% - 61% over full year 2022.
Webcast Information
Seer will host a conference call to discuss the first quarter 2023 financial results on Tuesday, May 9, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s current views with respect to certain current and future events and financial performance. Words such as “expects,” “anticipates,” “projects,” “intends,” “plans,” “believes,” “estimates,” variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company’s outlook for fiscal year 2023. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Quarterly Report on Form 10-Q, to be filed with the SEC, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Carrie Mendivil
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Karen Possemato
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Seer, Inc. | ||||||||
| UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue: | ||||||||
| Product | $ | 2,343 | $ | 2,149 | ||||
| Service | 69 | 79 | ||||||
| Related party | 1,306 | 1,070 | ||||||
| Grant and other | 335 | 14 | ||||||
| Total revenue | 4,053 | 3,312 | ||||||
| Cost of revenue: | ||||||||
| Product | 1,436 | 1,660 | ||||||
| Service | 7 | 14 | ||||||
| Related party | 478 | 394 | ||||||
| Grant and other | 64 | — | ||||||
| Total cost of revenue | 1,985 | 2,068 | ||||||
| Gross profit | 2,068 | 1,244 | ||||||
| Operating expenses: | ||||||||
| Research and development | 14,474 | 10,732 | ||||||
| Selling, general and administrative | 15,039 | 14,298 | ||||||
| Total operating expenses | 29,513 | 25,030 | ||||||
| Loss from operations | (27,445 | ) | (23,786 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 3,717 | 144 | ||||||
| Other expense | (231 | ) | (4 | ) | ||||
| Total other income | 3,486 | 140 | ||||||
| Net loss | $ | (23,959 | ) | $ | (23,646 | ) | ||
| Other comprehensive loss: | ||||||||
| Unrealized gain (loss) on available-for-sale securities | 1,158 | (1,691 | ) | |||||
| Comprehensive loss | $ | (22,801 | ) | $ | (25,337 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.38 | ) | $ | (0.38 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 63,543,094 | 62,003,504 | ||||||
| Seer, Inc. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (In thousands, except share and per share amounts) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 48,386 | $ | 53,208 | ||||
| Short-term investments | 303,708 | 368,031 | ||||||
| Accounts receivable, net | 4,735 | 4,315 | ||||||
| Related party receivables | 1,383 | 1,804 | ||||||
| Other receivables | 1,065 | 899 | ||||||
| Inventory | 3,718 | 4,627 | ||||||
| Prepaid expenses and other current assets | 4,380 | 2,098 | ||||||
| Total current assets | 367,375 | 434,982 | ||||||
| Long-term investments | 58,416 | 5,157 | ||||||
| Operating lease right-of-use assets | 26,944 | 27,003 | ||||||
| Property and equipment, net | 18,675 | 19,408 | ||||||
| Restricted cash | 524 | 524 | ||||||
| Other assets | 853 | 855 | ||||||
| Total assets | $ | 472,787 | $ | 487,929 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,956 | $ | 2,104 | ||||
| Accrued expenses | 7,175 | 8,298 | ||||||
| Deferred revenue | 263 | 133 | ||||||
| Operating lease liabilities, current | 2,188 | 1,842 | ||||||
| Other current liabilities | 172 | 207 | ||||||
| Total current liabilities | 11,754 | 12,584 | ||||||
| Operating lease liabilities, net of current portion | 27,684 | 28,032 | ||||||
| Other noncurrent liabilities | 360 | 320 | ||||||
| Total liabilities | 39,798 | 40,936 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of March 31, 2023 and December 31, 2022; zero shares issued and outstanding as of March 31, 2023 and December 31, 2022 | — | — | ||||||
| Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 59,694,350 and 59,366,077 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | 1 | 1 | ||||||
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 4,044,969 and 4,044,969 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | — | — | ||||||
| Additional paid-in capital | 676,536 | 667,739 | ||||||
| Accumulated other comprehensive loss | (93 | ) | (1,251 | ) | ||||
| Accumulated deficit | (243,455 | ) | (219,496 | ) | ||||
| Total stockholders’ equity | 432,989 | 446,993 | ||||||
| Total liabilities and stockholders’ equity | $ | 472,787 | $ | 487,929 | ||||
| Last Trade: | US$2.23 |
| Daily Change: | -0.03 -1.33 |
| Daily Volume: | 289,292 |
| Market Cap: | US$122.470M |
February 20, 2025 January 02, 2025 November 06, 2024 October 31, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
